

Voluntary recall of robaxin 750 mg due to dosage misprint

October 3 2018



(HealthDay)—Endo Pharmaceuticals is voluntarily recalling two lots of

Robaxin (methocarbamol tablets) 750 mg tablets (100-count bottles) due to incorrect dosage information.

According to the recall notice, the products have incorrect daily dosing [information](#) on the label due to a labeling error that misstates the daily dose as "two to four tablets four times daily" rather than the correct dosage of "two tablets three times daily."

The recall includes the following product lots: Robaxin 750 mg, 100 Count Bottle pack, Lot 216702P1, Expiration Date: September 2020; and Robaxin 750 mg, 100 Count Bottle pack, Lot 220409P1, Expiration Date: January 2021. No other lots of Robaxin are affected by this recall.

Significant drowsiness or dizziness may be experienced by patients who follow the incorrect directions. Following these directions could put them at risk for falls or an overdose, which could result in seizures, coma, or death. To [date](#), Endo Pharmaceuticals has not received any reports of patient harm associated with the recall.

For more information about the [recall](#), contact Endo Pharmaceuticals by phone at 1-800-462-ENDO (3636).

More information: [Endo Press Release](#)
[FDA Recall Notice](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: Voluntary recall of robaxin 750 mg due to dosage misprint (2018, October 3) retrieved 18 April 2024 from
<https://medicalxpress.com/news/2018-10-voluntary-recall-robaxin-mg-due.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.